Nintedanib is a tyrosine kinase inhibitor which has shown to reduce the progression of idiopathic pulmonary fibrosis (IPF). [1, 2] This is a single-center, retrospective observational study of IPF patients at a tertiary care center who were prescribed nintedanib. All patients were diagnosed to have IPF based on the prevalent ATS/ERS guidelines. [3] Clinical details including demographics, symptoms, duration of IPF, and use of pirfenidone and nintedanib were recorded. Side effects of nintedanib as well as tolerability of nintedanib compared to pirfenidone were also noted. Change in forced vital capacity (FVC) and symptoms after 6 months of use of nintedanib were analyzed.
We prescribed nintedanib in 25 patients with IPF. Of these, twenty patients started the drug and five patients did not start primarily due to high costs. Of the twenty patients, there were 15 males and five females. The age of the patients ranged from 45 to 80 years (mean 60 years). While 16 patients had used pirfenidone before starting nintedanib, four patients were directly started on nintedanib. The mean duration of IPF before starting nintedanib was 3.05 years. The mean duration of pirfenidone use before starting nintedanib was 2.9 years (5 months to 7 years). Reasons for switching from pirfenidone to nintedanib were disease progression despite pirfenidone (eight patients), gastric side effects (seven patients), and both worsening and side effects (one patient). The mean FVC at the time of starting nintedanib was 1.43 L (mean predicted 50.4%).
Follow-up pulmonary function tests (PFTs) after 6 months of nintedanib were available in only 12 patients out of twenty patients. The FVC of patients in whom PFTs were available was stable with decrease of FVC by a mean of 0.04 L at 6 months of starting nintedanib.
At the time of analysis, of the 20 patients who received nintedanib, 16 were alive and 4 had died. One patient underwent lung transplant, whereas another was awaiting a lung transplant. Nintedanib was continued in 12 patients and stopped in 8 patients. Reasons for stopping nintedanib were death in four patients, lung transplant in one patient, worsening of disease despite nintedanib in two patient, and Benign metastasizing leiomyoma (BML) arises from a histologically benign uterine leiomyoma. It is characterized by multiple smooth muscle nodules, most often located in the lung, abdominal cavity, retroperitoneum, muscular tissue, lymph nodes, blood vessels, or heart. The coexistence of BMLs in the lung and retroperitoneum is extremely rare. Herein, we report a rare case of simultaneous occurrence of multiple BMLs in the lung and retroperitoneum of a 42-year-old woman who had previously undergone hysterectomy to treat benign uterine leiomyoma.
A 42-years-old female patient was referred for the evaluation of cough, abdominal pain, and abnormal chest X-ray findings. She had a history of multiple uterine leiomyomas and had undergone myomectomy at 30 years of age, subsequently undergoing total abdominal hysterectomy, because of recurrent multiple uterine leiomyomas, at 33 years of age. When she was 39 years of age, an abdominal computed tomography (CT) scan revealed a 5 cm × 4 cm nodule in the distal portion of the left para-aortic region and a 46 cm × 26 cm nodule just to the left of and posterolateral to the bladder. At that time, laparotomy, with excisional biopsy, was performed. Examination of the biopsy sample revealed a leiomyoma that tested positive for estrogen and progesterone.
In the initial physical examination at our facility, palpable masses were identified in the left upper and left lower quadrants of the abdomen. Routine laboratory tests showed that the values for biochemical variables, including those for the tumor markers such as alpha-fetoprotein, cancer antigen 19-9, and cancer antigen 125, were within the normal ranges. A chest X-ray revealed well-defined masses, with several nodules in both lung fields. The patient was submitted to CT scans of the chest and abdomen. In the lungs, the CT scans revealed multiple nodules with regular borders, distributed randomly and bilaterally, the largest with a diameter of 4.6 cm [ Figure 1 ]. The abdominal scans showed a solid mass of approximately 18 cm × 13 cm, with regular borders and lobulated contours, that heterogeneously enhanced with contrast and filled the paravertebral area. To the right of and adjacent to the first abdominal mass were two additional masses, measuring 24 mm × 17 mm and 8 cm × 5 cm, respectively. In the pelvic adnexa, bilaterally, there were multiple solid lesions with lobulated contours, the largest being on the left and measuring approximately 4.6 cm × 3.3 cm. To identify the primary malignancy and metastatic lesions, we employed 18 F-fluorodeoxyglucose-positron emission tomography and CT (FDG-PET/CT). There was no pathologic FDG uptake to suggest the primary malignancy or metastatic lesions in any other part of the body. The retroperitoneal masses were excised. The patient subsequently underwent video-assisted thoracoscopic surgery with wedge resection of two of the nodules. Analysis of intraoperative frozen sections from the retroperitoneal tumors suggested leiomyoma. Microscopic examinations showed well-differentiated straight muscle cell bundles, although neither nuclear atypia nor mitotic activity was identified in the lung nodules or retroperitoneal masses. The proliferation index, as defined by the cell division marker Ki-67, was very low (<1%), and there was positive immunohistochemical staining for estrogen and progesterone receptors [ Figure 2 ]. The pathological findings of both the lung nodules and retroperitoneal masses confirmed the diagnosis of BML. The patient was started on gonadotropin-releasing hormone (GnRH) agonist goserelin. At this writing, she is undergoing regular follow-up evaluations.
BML is a rare disease that originates from a histologically benign uterine leiomyoma, and is usually found 3 months
